<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="concession" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">3.</segment>
<segment id="2" parent="1002" relname="preparation">Protocols to Induce Mature EC Phenotype</segment>
<segment id="3" parent="1004" relname="attribution">It is well known</segment>
<segment id="4" parent="1004" relname="span">that for clinical use , it is mandatory to generate cells</segment>
<segment id="5" parent="4" relname="elaboration">able to show a high degree of commitment .</segment>
<segment id="6" parent="1006" relname="span">This requirement fulfills not only functional issues , but also safety ones ,</segment>
<segment id="7" parent="6" relname="purpose">in order to prevent teratoma formation after implantation .</segment>
<segment id="8" parent="1008" relname="span">Thus , a prerequisite</segment>
<segment id="9" parent="1009" relname="span">to exploit iPSC-ECs in the clinical setting is the development of defined protocols</segment>
<segment id="10" parent="9" relname="purpose">to guide their differentiation into functional endothelial cells .</segment>
<segment id="11" parent="1011" relname="span">The ideal induction protocol should be reproducible , easy to perform and relatively quick</segment>
<segment id="12" parent="11" relname="purpose">in order to allow yielding an adequate quantity of homogeneous cells .</segment>
<segment id="13" parent="1014" relname="span">Current induction strategies include embryonic bodies</segment>
<segment id="14" parent="13" relname="restatement">( EB )</segment>
<segment id="15" parent="16" relname="preparation">generation ,</segment>
<segment id="16" parent="1015" relname="span">differentiation on monolayers and co-culture with primary cells (</segment>
<segment id="17" parent="1017" relname="preparation">Figure 4</segment>
<segment id="18" parent="1017" relname="joint">) .</segment>
<segment id="19" parent="1020" relname="span">IPSCs tend to self-assemble into three-dimensional</segment>
<segment id="20" parent="19" relname="elaboration">( 3D )</segment>
<segment id="21" parent="1022" relname="span">structures</segment>
<segment id="22" parent="21" relname="restatement">( EB )</segment>
<segment id="23" parent="1022" relname="circumstance">when grown in suspension .</segment>
<segment id="24" parent="1025" relname="span">From EBs , cell aggregates</segment>
<segment id="25" parent="24" relname="elaboration">encompassing all three germ layers develop ,</segment>
<segment id="26" parent="1017" relname="joint">and afterwards , within the positive mesodermal , EB cells tend to form vascular structures .</segment>
<segment id="27" parent="1028" relname="span">This method is affected by low efficiency</segment>
<segment id="28" parent="27" relname="restatement">( 1 â€“ 5 % )</segment>
<segment id="29" parent="1029" relname="contrast">and slow production rate ;</segment>
<segment id="30" parent="1030" relname="span">however , differentiation can be improved</segment>
<segment id="31" parent="30" relname="means">by adding proper growth factors to the culture medium .</segment>
<segment id="32" parent="1032" relname="span">Another approach involves a co-culture with primary cell lines</segment>
<segment id="33" parent="32" relname="elaboration">able to induce iPSC-EC differentiation toward mature ECs .</segment>
<segment id="34" parent="1017" relname="joint">In detail , Choi et al. directed hiPSCs into mature ECs in the presence of OP9 , a mouse bone marrow stromal cell line .</segment>
<segment id="35" parent="36" relname="attribution">The authors speculated</segment>
<segment id="36" parent="1035" relname="span">that these cells regulate iPSC induction via a paracrine signaling .</segment>
<segment id="37" parent="1038" relname="span">Monolayer differentiation holds a significantly higher efficiency</segment>
<segment id="38" parent="37" relname="elaboration">that depends on external factors , such as medium constituents ,</segment>
<segment id="39" parent="1039" relname="span">showing a final yield</segment>
<segment id="40" parent="39" relname="elaboration">that is still too low in the view of clinical applications .</segment>
<segment id="41" parent="1041" relname="span">To date , the best protocols</segment>
<segment id="42" parent="1042" relname="span">showing the highest EC yields were developed</segment>
<segment id="43" parent="1043" relname="joint">by culturing a monolayer of hiPSCs on a matrix-coated culture plate</segment>
<segment id="44" parent="1044" relname="span">and by treating them with different molecules or growth factors in a timed fashion</segment>
<segment id="45" parent="44" relname="purpose">in order to guide the progressive differentiation of hiPSCs toward the EC lineage .</segment>
<segment id="46" parent="1046" relname="span">In this context , GSK3 inhibitors play an important role among the set of molecules</segment>
<segment id="47" parent="1047" relname="span">necessary</segment>
<segment id="48" parent="47" relname="purpose">to induce the differentiation of pluripotent cells into mature ECs .</segment>
<segment id="49" parent="1050" relname="span">In particular , vascular progenitors derive during human development from latero-posterior mesoderm .</segment>
<segment id="50" parent="1052" relname="span">To specify mesoderm , Wnt signaling ,</segment>
<segment id="51" parent="50" relname="elaboration">which is activated by GSK3 inhibition ,</segment>
<segment id="52" parent="1051" relname="same_unit">is required .</segment>
<segment id="53" parent="1053" relname="span">In view of this , several authors have exploited GSK3 inhibitors</segment>
<segment id="54" parent="53" relname="purpose">to differentiate hiPSCs into ECs .</segment>
<segment id="55" parent="1056" relname="span">Patsch et al. exposed a monolayer of hiPSC to GSK3 inhibitor CHIR-99021</segment>
<segment id="56" parent="55" relname="restatement">( CHIR )</segment>
<segment id="57" parent="1057" relname="span">and to mesoderm inducer bone morphogenetic protein 4</segment>
<segment id="58" parent="57" relname="restatement">( BMP4 ) .</segment>
<segment id="59" parent="1060" relname="span">The combination of these two molecules led to the production of mature ECs in a relatively short time</segment>
<segment id="60" parent="59" relname="elaboration">( six days )</segment>
<segment id="61" parent="1059" relname="same_unit">with 80 % efficiency .</segment>
<segment id="62" parent="1048" relname="joint">However , mesoderm induction is only the first step of differentiation .</segment>
<segment id="63" parent="1063" relname="span">The second part starts upon mesodermal commitment</segment>
<segment id="64" parent="1064" relname="span">by exposing the cells to factors</segment>
<segment id="65" parent="64" relname="elaboration">that further induce the mature vascular phenotype .</segment>
<segment id="66" parent="1066" relname="span">Gu set up a protocol</segment>
<segment id="67" parent="1067" relname="span">through which , after 4 days of treatment with VEGF and bFGF ,</segment>
<segment id="68" parent="67" relname="elaboration">he produced mature ECs in only 8 days .</segment>
<segment id="69" parent="1070" relname="span">These cells ,</segment>
<segment id="70" parent="69" relname="circumstance">when tested ,</segment>
<segment id="71" parent="1069" relname="same_unit">were molecularly and functionally similar to native ECs .</segment>
<segment id="72" parent="1072" relname="span">Paik et al. added VEGF , bFGF and BMP4 to an already established protocol</segment>
<segment id="73" parent="72" relname="purpose">to produce mature ECs from hiPSCs within 12 days .</segment>
<segment id="74" parent="1075" relname="span">Although this protocol requires more time</segment>
<segment id="75" parent="1076" relname="span">compared to other ones</segment>
<segment id="76" parent="75" relname="elaboration">reported in literature ,</segment>
<segment id="77" parent="1074" relname="span">the aim of this study was different .</segment>
<segment id="78" parent="1078" relname="span">In fact , these cells were used</segment>
<segment id="79" parent="78" relname="purpose">to draw an RNA signature at different stage of differentiation .</segment>
<segment id="80" parent="1080" relname="span">The last step</segment>
<segment id="81" parent="80" relname="elaboration">included in the differentiation protocol is the purification of positive cells .</segment>
<segment id="82" parent="1082" relname="span">This step is essential</segment>
<segment id="83" parent="1083" relname="joint">to fish out a homogenous subset of cells</segment>
<segment id="84" parent="1084" relname="span">and to ensure the safety</segment>
<segment id="85" parent="84" relname="elaboration">needed for the future cell implantation and engraftment .</segment>
<segment id="86" parent="1086" relname="span">Cell sorting is usually performed</segment>
<segment id="87" parent="1087" relname="span">by using magnetic beads</segment>
<segment id="88" parent="87" relname="elaboration">on which surface specific antibodies are adsorbed .</segment>
<segment id="89" parent="1088" relname="span">These antibodies are directed against mature endothelial markers such as CD31 or VE-cadherin</segment>
<segment id="90" parent="89" relname="elaboration">( also known as CD144 ) .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="span" parent="1005" relname="preparation"/>
<group id="1004" type="span" parent="1003" relname="span"/>
<group id="1005" type="multinuc" parent="1002" relname="span"/>
<group id="1006" type="span" parent="1005" relname="joint"/>
<group id="1007" type="multinuc" parent="1005" relname="joint"/>
<group id="1008" type="span" parent="1007" relname="sequence"/>
<group id="1009" type="span" parent="8" relname="purpose"/>
<group id="1010" type="multinuc" parent="1007" relname="sequence"/>
<group id="1011" type="span" parent="1010" relname="joint"/>
<group id="1012" type="span" parent="1010" relname="joint"/>
<group id="1013" type="multinuc" parent="1016" relname="preparation"/>
<group id="1014" type="span" parent="1013" relname="same_unit"/>
<group id="1015" type="span" parent="1013" relname="same_unit"/>
<group id="1016" type="span" parent="1012" relname="span"/>
<group id="1017" type="multinuc" parent="1016" relname="span"/>
<group id="1019" type="multinuc" parent="1017" relname="joint"/>
<group id="1020" type="span" parent="1019" relname="same_unit"/>
<group id="1021" type="span" parent="1019" relname="same_unit"/>
<group id="1022" type="span" parent="1021" relname="span"/>
<group id="1025" type="span" parent="1017" relname="joint"/>
<group id="1028" type="span" parent="1017" relname="joint"/>
<group id="1029" type="multinuc" parent="1017" relname="joint"/>
<group id="1030" type="span" parent="1029" relname="contrast"/>
<group id="1032" type="span" parent="1017" relname="joint"/>
<group id="1035" type="span" parent="1017" relname="joint"/>
<group id="1037" type="span" parent="1017" relname="joint"/>
<group id="1038" type="span" parent="1037" relname="span"/>
<group id="1039" type="span" parent="1038" relname="elaboration"/>
<group id="1041" type="span" parent="1017" relname="joint"/>
<group id="1042" type="span" parent="41" relname="elaboration"/>
<group id="1043" type="multinuc" parent="42" relname="means"/>
<group id="1044" type="span" parent="1043" relname="joint"/>
<group id="1045" type="span" parent="1017" relname="joint"/>
<group id="1046" type="span" parent="1048" relname="background"/>
<group id="1047" type="span" parent="46" relname="elaboration"/>
<group id="1048" type="multinuc" parent="1045" relname="span"/>
<group id="1050" type="span" parent="1048" relname="joint"/>
<group id="1051" type="multinuc" parent="49" relname="purpose"/>
<group id="1052" type="span" parent="1051" relname="same_unit"/>
<group id="1053" type="span" parent="1048" relname="joint"/>
<group id="1055" type="multinuc" parent="1048" relname="joint"/>
<group id="1056" type="span" parent="1055" relname="same_unit"/>
<group id="1057" type="span" parent="1055" relname="same_unit"/>
<group id="1059" type="multinuc" parent="1048" relname="joint"/>
<group id="1060" type="span" parent="1059" relname="same_unit"/>
<group id="1063" type="span" parent="1048" relname="joint"/>
<group id="1064" type="span" parent="63" relname="means"/>
<group id="1066" type="span" parent="1048" relname="joint"/>
<group id="1067" type="span" parent="66" relname="elaboration"/>
<group id="1069" type="multinuc" parent="1048" relname="joint"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1072" type="span" parent="1048" relname="joint"/>
<group id="1073" type="span" parent="1048" relname="joint"/>
<group id="1074" type="span" parent="1077" relname="background"/>
<group id="1075" type="span" parent="77" relname="concession"/>
<group id="1076" type="span" parent="74" relname="elaboration"/>
<group id="1077" type="multinuc" parent="1073" relname="span"/>
<group id="1078" type="span" parent="1077" relname="joint"/>
<group id="1079" type="span" parent="1077" relname="joint"/>
<group id="1080" type="span" parent="1081" relname="preparation"/>
<group id="1081" type="multinuc" parent="1079" relname="span"/>
<group id="1082" type="span" parent="1081" relname="joint"/>
<group id="1083" type="multinuc" parent="82" relname="purpose"/>
<group id="1084" type="span" parent="1083" relname="joint"/>
<group id="1086" type="span" parent="1081" relname="joint"/>
<group id="1087" type="span" parent="86" relname="means"/>
<group id="1088" type="span" parent="1081" relname="joint"/>
	</body>
</rst>
